Daeseung Lee
Chief Executive Officer
Physician-scientist who left clinical practice to bring spatial biology into oncology drug discovery.
10 articles
Portrai Insights
Insights on data analysis, AI, and the platform we're building at Portrai.
Latest
14 articles
Engineering-12 min read
Designing VGL — a multimodal foundation model for cancer cell biology
How we built Vision-Gene-Language: combining histopathology images, gene expression, and clinical text into one model that classifies tumor cells at scale.
HCHongyoon Choi-Apr 22, 2026
AI / ML-9 min read
Benchmarking spatial transcriptomics models — what we measure, and why
Most public benchmarks for spatial transcriptomics over-index on a few well-curated tissues. We share the evaluation suite Portrai uses internally to keep VGL and PortraiTME™ honest.
HCHongyoon Choi-Apr 15, 2026
Research Journal-18 min read
Engineering a precision-glycosylated clickable albumin nanoplatform
How Portrai's team built a glyco-clickable HSA nanoplatform for tumor-microenvironment targeting, validated dual-modality with PET imaging + spatial transcriptomics.
HIHyung-Jun Im-Apr 14, 2026
Drug Discovery-14 min read
Mapping drug distribution at single-cell resolution
PortraiDRUG turns spatial transcriptomics into a quantitative readout of where a payload actually lands. Here's why we think this is the missing piece for ADC and RPT design.
KNKwonjoong Na-Apr 4, 2026
Drug Discovery-8 min read
Target-based understanding of the termination of the AMG 794 clinical trial — a deep dive with spatial transcriptomics
Why did AMG 794 stop, and what does spatial transcriptomics tell us about the target landscape? A deep dive into the clinical trial termination through the lens of tissue-level biology.
DLDaeseung Lee-Dec 1, 2025
Drug Discovery-9 min read
Unlocking the full potential of bispecific antibodies with PortraiTARGET™ POR-PBPK
PortraiTARGET™ POR-PBPK combines spatial transcriptomics with physiologically-based pharmacokinetic modeling to predict tissue-level bispecific antibody exposure — up to 4.5× over monospecifics in the same tumor context.
DLDaeseung Lee-Jun 1, 2025
Research Journal-5 min read
AACR 2025 — Portrai abstracts
Eleven posters spanning bispecific ADC target pairs, image-based ST platform comparisons, in-silico ADC modeling, CAF-targeting antibodies, CELLama, and AI lymphocyte identification in NSCLC.
DLDaeseung Lee-Apr 8, 2025
Spatial Biology-5 min read
Weekly data spotlight — cost-effective single-cell analysis through spatial transcriptomics
STAMP profiles individual cells via image-based spatial transcriptomics — ~50× cheaper per cell than scRNA-seq, with rare-cell detection at 1:100,000 dilutions and direct visual validation.
DLDaeseung Lee-Oct 19, 2024
Research Journal-9 min read
Spatial transcriptomics reveals spatially diverse cancer-associated fibroblasts in lung squamous cell carcinoma linked to tumor progression
Image-based spatial transcriptomics across 33 LUSC patients shows CAF–tumor epithelium spatial interactions correlate with tumor size, metabolic activity, and recurrence-free survival — with glycolysis-upregulated fibroblast regions in barcode ST.
DLDaeseung Lee-Aug 1, 2024
WRITTEN BY
Portrai's Authors
Capturing and compounding Portrai's insights.
Hongyoon Choi
Chief Technology Officer
Builds the algorithms that turn spatial transcriptomics into actionable target intelligence.
2 articles
Hyung-Jun Im
Chief Scientific Officer
Nuclear medicine specialist linking imaging biomarkers to next-generation radiopharmaceuticals.
1 articles
Kwonjoong Na
Chief Medical Officer
Translates platform insights into IND-enabling decisions across oncology programs.
1 articles
Taesoo Shin
Senior Research Scientist
Spatial transcriptomics methodology lead. Builds Portrai's analysis pipelines that turn raw spot-level data into publishable cell-composition maps.
0 articles